Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Express Scripts
Boehringer Ingelheim
Colorcon
Moodys

Last Updated: September 26, 2022

Details for Patent: 8,420,663


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,420,663 protect, and when does it expire?

Patent 8,420,663 protects RELISTOR and is included in two NDAs.

This patent has thirty-five patent family members in seventeen countries.

Summary for Patent: 8,420,663
Title:Peripheral opioid receptor antagonists and uses thereof
Abstract: The present invention provides a compound of formula I: ##STR00001## wherein X.sup.-, R.sup.1, and R.sup.2 are as defined herein, and compositions thereof.
Inventor(s): Bazhina; Nataliya (Tappan, NY), Donato, III; George Joseph (Swarthmore, PA), Fabian; Steven R. (Barnegat, NJ), Lokhnauth; John (Fair Lawn, NJ), Megati; Sreenivasulu (New City, NY), Melucci; Charles K. (Highland Mills, NY), Ofslager; Christian (Newburgh, NY), Patel; Niketa (Lincoln Park, NJ), Radebaugh; Galen (Chester, NJ), Shah; Syed M. (East Hanover, NJ), Szeliga; Jan (Croton on Hudson, NY), Zhang; Huyi (Garnerville, NY), Zhu; Tianmin (Monroe, NY)
Assignee: Wyeth (Madison, NJ)
Application Number:13/570,836
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,420,663
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,420,663

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-002 Sep 27, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF OPIOID-INDUCED CONSTIPATION See Plans and Pricing
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-001 Apr 24, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF OPIOID-INDUCED CONSTIPATION See Plans and Pricing
Salix Pharms RELISTOR methylnaltrexone bromide SOLUTION;SUBCUTANEOUS 021964-003 Sep 27, 2010 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF OPIOID-INDUCED CONSTIPATION See Plans and Pricing
Salix RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF OPIOID-INDUCED CONSTIPATION See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,420,663

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 073520 See Plans and Pricing
Australia 2009298500 See Plans and Pricing
Brazil 122020013665 See Plans and Pricing
Brazil PI0919539 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Colorcon
Merck
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.